SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): AUGUST 25, 2000
COMMISSION FILE NUMBER 0-19467
MEDAMICUS, INC.
(Exact name of small business issuer in its charter)
MINNESOTA 41-1533300
(State of Incorporation) (IRS Employer Identification No.)
15301 HIGHWAY 55 WEST, PLYMOUTH, MN 55447
(Address of principal executive office, including zip code)
(612) 559-2613
(Registrant's telephone number, including area code)
N/A
--------------------------------------------------------------------------------
Former name, former address and former fiscal year, if changed since last report
<PAGE>
ITEM 5. OTHER EVENTS
On August 25, 2000, MedAmicus, Inc. (the "Company") entered into an agreement
with Med-Design Corporation for the right to manufacture and distribute
Med-Design's center-line retractable Safety Seldinger Introducer Needle.
The Company will market the Safety Seldinger Needle initially to its customer
base in the venous access market including pacing, port and dialysis
applications, as it explores with Med-Design channels of distribution into other
potential markets.
The Companies have also signed an agreement to develop an innovative
percutaneous delivery device using Med-Design's centerline retraction
technology.
The foregoing information is only a summary and is qualified in its entirety by
the information contained in the documents filed as exhibits to this Form 8-K.
ITEM 7 - FINANCIAL STATEMENTS AND EXHIBITS
* EXHIBIT 10.1 DEVELOPMENT AND LICENSING AGREEMENT FOR SAFETY "SELDINGER"
NEEDLE DEVICE BETWEEN MED-DESIGN CORPORATION AND MEDAMICUS, INC., DATED
AUGUST 25, 2000 (PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED PURSUANT TO A
CONFIDENTIAL TREATMENT REQUEST FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION CONTEMPORANEOUSLY HEREWITH).
* EXHIBIT 10.2 DEVELOPMENT AND LICENSING AGREEMENT FOR SAFETY INTRODUCER
BETWEEN MED-DESIGN CORPORATION ANDMEDAMICUS, INC., DATED AUGUST 25, 2000
(PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED PURSUANT TO A CONFIDENTIAL
TREATMENT REQUEST FILED WITH THE SECURITIES AND EXCHANGE COMMISSION
CONTEMPORANEOUSLY HEREWITH).
* EXHIBIT 99.1 PRESS RELEASE ANNOUNCING EXECUTION OF DEVELOPMENT AND
LICENSING AGREEMENTS, DATED AUGUST 28, 2000.
SIGNATURE
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized:
MEDAMICUS, INC.
Date: September 18, 2000 By: /s/ James D. Hartman
President, Chief Executive Officer and Chief
Financial Officer
2
